About Soterya
Soterya, Inc., based in Boston, makes Korus, a bed with pressure and motion sensors and air-powered actuators. It detects a person's body position and moves them without anyone's help. The company plans versions for home care, long-term care facilities and hospitals, including epilepsy units, and later a consumer sleep line.
Its first goal was to prevent sudden unexpected death in epilepsy (SUDEP), work that the National Institutes of Health has funded since 2021. Co-founder Lina Williamson is CEO. Soterya plans pilots with care facilities in 2027, subject to regulatory clearance.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Oct 13, 2026 | $850,000of $2.0M target | 3 | $283K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Soterya
Investors backed Soterya for Korus, a bed that senses a person's position and turns them on its own when no caregiver is there. Its first target is sudden unexpected death in epilepsy, which mostly strikes face-down and unwitnessed. The National Institutes of Health has put about $3.5 million into that work since 2021. The company now plans versions for nursing homes and people aging at home.
The problem it targets
Soterya's view is that nurses, caregivers and relatives still turn people in bed by hand, around the clock. Aging populations and a nursing shortage mean that help is often missing. In epilepsy the risk is acute: 86% of SUDEP deaths occur face-down and unwitnessed. Pressure injuries cost the United States $26.8 billion a year.
What the product does
Pressure and motion sensors map the body across 64 zones in real time, and machine-learning models on the device decide when to move the person, with no cloud connection. Pneumatic actuators then shift the person quietly, with force limits and fail-safe defaults. During a seizure, Korus is designed to roll the person into a safer position; in care homes, it would take over the two-hourly turns that prevent bedsores.
Who backs it
The National Institutes of Health funds Soterya's SUDEP device through its neurology institute, NINDS. It gave a $502,561 first-phase small business grant in 2021, then second-phase awards of about $3 million from 2024 to 2026, NIH records show. The company is now raising money to launch its home and long-term care versions.
We wrote this summary from public statements by Soterya and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Soterya's Form D filed Oct 13, 2026.
Sources
- SECSoterya, Inc. filing history
- Company siteAbout page (leadership) on soteryabio.com
- ResearchNIH RePORTER: A Device to Prevent Sudden Unexpected Death in Epilepsy (SUDEP), R43/R44NS120394
- ResearchSBIR.gov: Soterya Phase I award, $502,561 (2021)
- CompanyKorus for institutions on soteryabio.com (piloting 2027)